Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NamePrimidone
Accession NumberDB00794  (APRD00549)
Typesmall molecule
Groupsapproved
Description

An antiepileptic agent related to the barbiturates; it is partly metabolized to phenobarbital in the body and owes some of its actions to this metabolite. Adverse effects are reported to be more frequent than with phenobarbital. (From Martindale, The Extra Pharmacopoeia, 30th ed, p309)

Structure
Thumb
Synonyms
SynonymLanguageCode
DesoxyphenobarbitalNot AvailableIS
PrimacloneNot AvailableIS
PrimidonGermanINN
PrimidonaSpanishINN
PrimidoneFrenchINN
PrimidonumLatinINN
SaltsNot Available
Brand names
NameCompany
LiskantinDesitin
MizodinUnia
MylepsinumNot Available
MysolineAstraZeneca
PridonaPsicofarma
PrimidApsen
PrysolineRekah
SertanAlkaloida
Brand mixturesNot Available
Categories
CAS number125-33-7
WeightAverage: 218.2518
Monoisotopic: 218.105527702
Chemical FormulaC12H14N2O2
InChI KeyInChIKey=DQMZLTXERSFNPB-UHFFFAOYSA-N
InChI
InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)
IUPAC Name
5-ethyl-5-phenyl-1,3-diazinane-4,6-dione
SMILES
CCC1(C(=O)NCNC1=O)C1=CC=CC=C1
Mass Specshow(9.01 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassBenzenoids
ClassBenzene and Substituted Derivatives
SubclassNot Available
Direct parentBenzene and Substituted Derivatives
Alternative parentsDiazinanes; Secondary Carboxylic Acid Amides; Polyamines; Carboxylic Acids
Substituentssecondary carboxylic acid amide; carboxamide group; carboxylic acid derivative; polyamine; carboxylic acid; organonitrogen compound
Classification descriptionThis compound belongs to the benzene and substituted derivatives. These are aromatic compounds containing at least one benzene ring.
Pharmacology
IndicationFor the treatment of epilepsy
PharmacodynamicsPrimidone is a barbiturate with anticonvulsant properties. Primidone, either alone or used concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. Primidone raises electro- or chemoshock seizure thresholds or alters seizure patterns in experimental animals. Primidone per se has anticonvulsant activity as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). In addition to its anticonvulsant activity, Primidone potentiates that of phenobarbital in experimental animals.
Mechanism of actionPrimidone is a GABA receptor agonist. The mechanism of Primidone's antiepileptic action is not known.
Absorption90 to 100%
Volume of distributionNot Available
Protein binding70%
Metabolism

Hepatic

SubstrateEnzymesProduct
Primidone
PhenobarbitalDetails
Route of eliminationNot Available
Half life3-23 hours
ClearanceNot Available
ToxicitySymptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9907
Blood Brain Barrier + 0.9642
Caco-2 permeable - 0.5593
P-glycoprotein substrate Substrate 0.5222
P-glycoprotein inhibitor I Non-inhibitor 0.536
P-glycoprotein inhibitor II Non-inhibitor 0.9048
Renal organic cation transporter Non-inhibitor 0.8298
CYP450 2C9 substrate Non-substrate 0.7961
CYP450 2D6 substrate Non-substrate 0.9116
CYP450 3A4 substrate Non-substrate 0.6863
CYP450 1A2 substrate Non-inhibitor 0.9045
CYP450 2C9 substrate Non-inhibitor 0.9071
CYP450 2D6 substrate Non-inhibitor 0.924
CYP450 2C19 substrate Non-inhibitor 0.9026
CYP450 3A4 substrate Non-inhibitor 0.8309
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8682
Ames test AMES toxic 0.9107
Carcinogenicity Non-carcinogens 0.7814
Biodegradation Not ready biodegradable 0.982
Rat acute toxicity 2.1941 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9912
hERG inhibition (predictor II) Non-inhibitor 0.8735
Pharmacoeconomics
Manufacturers
  • Xcel pharmaceuticals
  • Valeant pharmaceuticals international
  • Amneal pharmaceutical
  • Dr reddys laboratories ltd
  • Impax laboratories inc
  • Lannett co inc
  • Mutual pharmaceutical co inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
TabletOral
Prices
Unit descriptionCostUnit
Primidone powder10.56USDg
Mysoline 250 mg tablet6.52USDtablet
Mysoline 50 mg tablet1.26USDtablet
Primidone 250 mg tablet1.02USDtablet
Primidone 50 mg tablet0.51USDtablet
Apo-Primidone 250 mg Tablet0.09USDtablet
Apo-Primidone 125 mg Tablet0.06USDtablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point281.5 °CPhysProp
water solubility500 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.91HANSCH,C ET AL. (1995)
logS-2.64ADME Research, USCD
Predicted Properties
PropertyValueSource
water solubility1.04e+00 g/lALOGPS
logP0.62ALOGPS
logP1.12ChemAxon
logS-2.3ALOGPS
pKa (strongest acidic)11.5ChemAxon
pKa (strongest basic)-6.2ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count2ChemAxon
hydrogen donor count2ChemAxon
polar surface area58.2ChemAxon
rotatable bond count2ChemAxon
refractivity59.04ChemAxon
polarizability22.44ChemAxon
number of rings2ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis ReferenceNot Available
General Reference
  1. Murphy K, Delanty N: Primary Generalized Epilepsies. Curr Treat Options Neurol. 2000 Nov;2(6):527-542. Pubmed
  2. Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S: Unverricht-Lundborg disease with cystatin B gene abnormalities. Pediatr Neurol. 2002 Jan;26(1):55-60. Pubmed
  3. Brown GM, Stone GH, Rathbone MP: Primidone and rapid cycling affective disorders. Lancet. 1993 Oct 9;342(8876):925. Pubmed
  4. Schaffer LC, Schaffer CB, Caretto J: The use of primidone in the treatment of refractory bipolar disorder. Ann Clin Psychiatry. 1999 Jun;11(2):61-6. Pubmed
  5. Young MC, Hughes IA: Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone. Acta Paediatr Scand. 1991 Jan;80(1):120-4. Pubmed
External Links
ResourceLink
KEGG DrugD00474
KEGG CompoundC07371
PubChem Compound4909
PubChem Substance46507775
ChemSpider4740
Therapeutic Targets DatabaseDAP000678
PharmGKBPA451105
Drug Product Database396761
RxListhttp://www.rxlist.com/cgi/generic2/primid.htm
Drugs.comhttp://www.drugs.com/cdi/primidone.html
WikipediaPrimidone
ATC CodesD08AC04N03AA03S03AA05S01AX08R01AX07R02AA18
AHFS Codes
  • 28:12.04
PDB EntriesNot Available
FDA labelshow(108 KB)
MSDSshow(65.5 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe barbiturate, primidone, decreases the anticoagulant effect of acenocoumarol.
AminophyllineThe barbiturate, primidone, decreases the effect of aminophylline.
AnisindioneThe barbiturate, primidone, decreases the anticoagulant effect of anisindione.
AsenapinePrimidone is a CYP1A2 inducer and may increase metabolism of asenapine.
BendamustineCYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine.
BetamethasoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, betamethasone.
ChlorotrianiseneThe enzyme inducer, primidone, decreases the effect of the hormone agent, chlorotrianisene.
ClomifeneThe enzyme inducer, primidone, decreases the effect of the hormone agent, clomifene.
Conjugated EstrogensThe enzyme inducer, primidone, decreases the effect of the hormone agent, conjugated estrogens.
Cortisone acetateThe barbiturate, primidone, may decrease the effect of the corticosteroid, cortisone acetate.
CyclosporineThe barbiturate, primidone, increases the effect of cyclosporine.
DexamethasoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, dexamethasone.
DicoumarolThe barbiturate, primidone, decreases the anticoagulant effect, dicumarol.
DiethylstilbestrolThe enzyme inducer, primidone, may decrease the effect of the hormone agent, diethylstilbestrol.
DoxycyclineThe anticonvulsant, primidone, decreases the effect of doxycycline.
DyphyllineThe barbiturate, primidone, decreases the effect of dyphylline.
EstradiolThe enzyme inducer, primidone, decreases the effect of the hormone agent, estradiol.
Estradiol valerate/DienogestAffects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
EstriolThe enzyme inducer, primidone, decreases the effect of the hormone agent, estriol.
EstroneThe enzyme inducer, primidone, decreases the effect of the hormone agent, estrone.
EstropipateThe enzyme inducer, primidone, decreases the effect of the hormone agent, estropipate.
Ethinyl EstradiolThis product may cause a slight decrease of contraceptive effect
EtravirineEtravirine, when used concomitantly with Primidone (primarily metabolized to phenobarbital), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
FelbamateFelbamate may increase the effect and toxicity of primidone.
FelodipineThe barbiturate, primidone, decreases the effect of felodipine.
FludrocortisoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, fludrocortisone.
Folic AcidFolic acid decreases the effect of anticonvulsant, primidone.
GefitinibThe CYP3A4 inducer, primidone, may decrease the serum concentration and therapeutic effects of gefitinib.
GriseofulvinThe barbiturate, primidone, decreases the effect of griseofulvin.
HydrocortisoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, hydrocortisone.
LevonorgestrelPhenobarbital decreases the effect of levonorgestrel
Medroxyprogesterone AcetateThe enzyme inducer, primidone, may decrease the effect of the hormone, medroxyprogesterone.
Megestrol acetateThe enzyme inducer, primidone, may decrease the effect of the hormone, megestrol.
MestranolThis product may cause a slight decrease of contraceptive effect
MethadoneThe barbiturate, primidone, decreases the effect of methadone.
MethoxyfluraneThe barbiturate, primidone, increases the renal toxicity of methoxyflurane.
MethylprednisoloneThe barbiturate, primidone, may decrease the effect of the corticosteroid, methylprednisolone.
MetoprololThe barbiturate decreases the effect of metabolized beta-blocker
MetronidazoleThe barbiturate, primidone, decreases the effect of metronidazole.
NifedipineThe barbiturate, primidone, decreases the effect of the calcium channel blocker, nifedipine.
NorethindroneThis product may cause a slight decrease of contraceptive effect
OxtriphyllineThe barbiturate, primidone, decreases the effect of oxtriphylline.
ParamethasoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, paramethasone.
PrednisoloneThe barbiturate, primidone, may decrease the effect of the corticosteroid, prednisolone.
PrednisoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, prednisone.
PropranololThe barbiturate decreases the effect of metabolized beta-blocker
QuinestrolThe enzyme inducer, primidone, decreases the effect of the hormone agent, quinestrol.
QuinidineThe anticonvulsant, primidone, decreases the effect of quinidine.
RoflumilastAffects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
RufinamideIncreases clearance of rufinamide thus decreasing plasma concentration of rufinamide.
TelithromycinPrimidone may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
TemsirolimusPrimidone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
TheophyllineThe barbiturate, primidone, decreases the effect of theophylline.
TramadolPrimidone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
TrazodoneThe CYP3A4 inducer, Primidone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Primidone is initiated, discontinued or dose changed.
TretinoinThe strong CYP2C8 inducer, Primidone, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Primidone is initiated, discontinued or dose changed.
TriamcinoloneThe barbiturate, primidone, may decrease the effect of the corticosteroid, triamcinolone.
TriprolidineThe CNS depressants, Triprolidine and Primidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
VandetanibDecreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
VerapamilThe barbiturate, primidone, decreases the effect of the calcium channel blocker, verapamil.
VoriconazoleThe barbiturate, primidone, decreases the effect of voriconazole.
WarfarinThe barbiturate, primidone, decreases the anticoagulant effect of warfarin.
Food Interactions
  • Avoid alcohol.
  • Avoid high doses of caffeine.
  • Take with food to reduce gastric irritation.

1. Gamma-aminobutyric acid receptor subunit alpha-1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-1 P14867 Details

References:

  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. Pubmed
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  6. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  7. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

2. Gamma-aminobutyric acid receptor subunit alpha-2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-2 P47869 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed

3. Gamma-aminobutyric acid receptor subunit alpha-3

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-3 P34903 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed

4. Gamma-aminobutyric acid receptor subunit alpha-4

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-4 P48169 Details

References:

  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed

5. Gamma-aminobutyric acid receptor subunit alpha-5

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-5 P31644 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed

6. Gamma-aminobutyric acid receptor subunit alpha-6

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-6 Q16445 Details

References:

  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed

7. Neuronal acetylcholine receptor subunit alpha-4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-4 P43681 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. Pubmed
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed

8. Neuronal acetylcholine receptor subunit alpha-7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-7 P36544 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. Pubmed
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed

9. Glutamate receptor 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor 2 P42262 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed

10. Glutamate receptor ionotropic, kainate 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor ionotropic, kainate 2 Q13002 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed

11. GABA-A receptor (anion channel)

Kind: protein group

Organism: Human

Pharmacological action: yes

Actions: positive allosteric modulator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-1 P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2 P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3 P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4 P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5 P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6 Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1 P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2 P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3 P28472 Details
Gamma-aminobutyric acid receptor subunit delta O14764 Details
Gamma-aminobutyric acid receptor subunit epsilon P78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1 Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2 P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3 Q99928 Details
Gamma-aminobutyric acid receptor subunit pi O00591 Details
Gamma-aminobutyric acid receptor subunit theta Q9UN88 Details

References:

  1. ChEMBL Compound Report Card (Accessed December 2013)

1. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Application available online: The P450 Program
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2B6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2B6 P20813 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12